Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
218.42
-4.03 (-1.81%)
At close: Oct 9, 2026, 4:00 PM EDT
218.00
-0.42 (-0.19%)
After-hours: Oct 9, 2026, 7:53 PM EDT
Jazz Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 22 analysts polled by S&P Global, Jazz Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $294.64. The average 1-year stock price forecast is 34.90% higher than the current stock price, while the lowest is $225 (+3.01%) and the highest is $337 (+54.29%).
Price Target: $294.64 (+34.90%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Jazz Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 11 | 11 | 13 | 13 |
| Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Hold | 1 | 1 | 1 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 20 | 20 | 22 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Maintains $307 → $313 | Buy | Maintains | $307 → $313 | +43.30% | Oct 9, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $299 → $296 | Buy | Maintains | $299 → $296 | +35.52% | Oct 8, 2026 |
| Truist Financial | Truist Financial | Buy Maintains $281 → $286 | Buy | Maintains | $281 → $286 | +30.94% | Oct 7, 2026 |
| Citi | Citi | Buy Initiates $325 | Buy | Initiates | $325 | +48.80% | Sep 30, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $310 | Buy | Reiterates | $310 | +41.93% | Sep 28, 2026 |
Financial Forecast
Revenue This Year
4.72B
from 4.27B
Increased by 10.61%
Revenue Next Year
4.99B
from 4.72B
Increased by 5.76%
EPS This Year
21.65
from 8.38
Increased by 158.32%
EPS Next Year
25.82
from 21.65
Increased by 19.25%
EPS and Forward PE are based on non-GAAP adjusted numbers.